secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001847903-23-000113
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Centessa shareholders approve all proposals at 2023 annual meeting
------------------------------------------------------------------

- Re-elected directors Carol Stuckley, Brett Zbar, and Mathias Hukkelhoven with over 99.5% support.
- KPMG reappointed as UK statutory auditor and independent registered public accounting firm for FY2023.
- Adopted UK statutory annual accounts for FY2022; no dividend recommended by directors.
- Advisory vote approved directors' remuneration report for FY2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/cnta-20230622.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000113

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer